Biotech Values

[NP1986]

but the results and the known effect of the drug have to give one some solid confidence that this drug works, it works well, and it works well compared in the context of the competitive environment.

I respectfully disagree. I don't think one should extrapolate the results from the MTC trial to an effect on bone metastases, and it certainly doesn't clarify whether cabozantinib would have any competitive advantages over currently available drugs for prostate cancer.